C4 Therapeutics Rings the Closing Bell

ABOUT THIS EVENT

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Andrew Hirsch, President and Chief Executive Officer of C4 Therapeutics, rings the Closing Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore